621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study's design was significant because it aimed to provide a head-to-head comparison of two distinct and highly effective drug classes—a GLP-1 receptor agonist and an SGLT2 inhibitor—in a critical patient populat…
This research holds significant promise for public health, as it targets a critical window for intervention to prevent Type 2 Diabetes (T2DM) in a high-risk group. Successful outcomes could establish semaglutide as a …
Understanding the precise gastric emptying kinetics in both healthy individuals and GLP-1 agonist users is critically important for optimizing treatment strategies and patient safety. The findings could lead to update…
This trial is crucial because it directly addresses a significant unmet need in treating HFpEF, especially in the context of obesity. If successful, it could establish Semaglutide as a novel therapeutic strategy for i…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
This compelling case report highlights the transformative potential of Semaglutide as a crucial therapeutic tool for obese patients awaiting lung transplantation. By facilitating rapid and significant weight loss, Sem…
The commentary underscores the transformative potential of Semaglutide in addressing the multifaceted challenges of obesity and its associated comorbidities. Its demonstrated efficacy across multiple physiological sys…
This review provides crucial evidence to guide clinical decision-making and optimize the allocation of these highly effective therapies, especially in healthcare systems facing resource constraints. By identifying spe…
This study provides crucial insights into the financial sustainability of covering highly effective, yet expensive, medications like Semaglutide within Medicare. The findings underscore the the significant potential f…
This study provides compelling evidence that semaglutide offers a dual therapeutic benefit, simultaneously addressing liver fibrosis and cardiovascular risk in patients already at high risk for advanced liver disease.…
The termination of a Phase 2 trial for a novel compound like PF-07081532 is a significant event in drug development, often signaling issues with safety, efficacy, or strategic priorities. While the specific reasons fo…
This study provides compelling evidence that semaglutide 2.4 mg once-weekly is a highly effective and generally well-tolerated treatment for chronic weight management in adults with overweight or obesity. The magnitud…
While this specific study was withdrawn, the broader context of its aims remains highly relevant for Type 2 Diabetes management. Understanding real-world effectiveness and adherence is crucial for optimizing patient o…
This planned randomized clinical trial holds significant promise for addressing the growing public health challenge of cognitive decline in older adults with Type 2 diabetes. If successful, the findings could provide …
This study is significant because it directly addresses the need for ethnically diverse clinical data in obesity treatment. The findings will provide crucial insights into how Semaglutide 2.4mg performs in the Latino …
Understanding the interplay between GLP-1 receptor agonists like semaglutide and the ghrelin system is crucial for optimizing obesity treatments. If blocking the ghrelin receptor with LEAP2 proves beneficial, it could…
This research holds significant promise as it investigates a novel approach to treating psoriasis by targeting its metabolic underpinnings, rather than just skin symptoms. If successful, it could demonstrate that Sema…
This study is crucial for enhancing patient safety during surgical procedures for individuals on GLP-1 agonists. The findings will help identify specific patient populations who require additional risk stratification,…
The withdrawal of this study means a valuable opportunity to directly compare these important first-line diabetes treatments has been lost. Had it proceeded, the trial could have provided critical head-to-head data, p…
This research is profoundly important as Type 2 Diabetes (T2D) significantly elevates the risk of severe cerebrovascular events like stroke, and understanding semaglutide's direct impact on brain health is critical. I…
The anticipated findings from this study underscore the potential of semaglutide 2.4 mg as a highly effective treatment option for individuals managing both Type 2 Diabetes and obesity. By addressing both conditions s…
The high and increasing prevalence of adolescent severe obesity underscores the urgent need for more effective and sustainable treatment strategies. If successful, this trial could demonstrate that combining semagluti…
This study is profoundly crucial for validating the cardiovascular benefits of semaglutide 2.4 mg in a real-world setting, offering invaluable data that complements and extends findings from highly controlled clinical…
Understanding the optimal pre-procedural management for patients on GLP-1RAs like semaglutide is critical for patient safety and procedural efficacy during endoscopy. If a one-week discontinuation significantly reduce…
This study holds significant implications for the obesity treatment landscape. A successful outcome, demonstrating comparable or superior efficacy and safety, could introduce a new, potentially more accessible or cost…
This trial is critically important because it directly compares the anti-atherosclerotic potential of newer, cardio-protective antidiabetic drugs against a long-standing standard in a high-risk population. If semaglut…
Understanding age-specific brain responses to GLP-1RAs is critically important for optimizing obesity treatment strategies across the lifespan. This research could reveal fundamental differences in how the developing …
This research is important because it provides real-world evidence for oral semaglutide's effectiveness outside of highly controlled clinical trial settings. Understanding its performance in routine clinical practice,…
This study is significant because it specifically investigates Semaglutide's efficacy and safety in East Asian subjects, addressing a critical gap in demographic representation within clinical trials for overweight an…
The potential findings from this study could be transformative for obesity management, offering a strategy to mitigate the undesirable muscle loss often associated with significant weight reduction. If successful, thi…
This planned study holds significant promise, as it could establish a novel pharmacological strategy to improve outcomes for atrial fibrillation patients with obesity undergoing ablation. If successful, the findings w…
This research is significant because it explores a novel therapeutic approach for acute pulmonary embolism, a condition with limited long-term treatment options beyond anticoagulation. If Semaglutide demonstrates a po…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
Understanding the long-term impact of semaglutide on appetite and eating behavior is crucial for optimizing obesity treatment strategies. If the study demonstrates sustained improvements in these areas, it could provi…
This foundational Phase 1 study is a critical early step in the development of NN9535 (semaglutide), a compound now widely known for its efficacy in type 2 diabetes and obesity. The successful completion of this trial…
This study is significant because it evaluates a novel approach to personalizing semaglutide treatment, which could revolutionize how obesity and excess weight are managed. By providing healthcare professionals with a…
The successful completion of this trial could have significant implications for the treatment landscape of Type 2 Diabetes. If QLG2065 demonstrates comparable efficacy and safety to Ozempic®, it would introduce a new,…